{"organizations": [], "uuid": "5ecc00079c39931c09b1da2c87fff40836cc068d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180411.html", "section_title": "Archive News &amp; Video for Wednesday, 11 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tesaro-and-medison-enter-into-excl/brief-tesaro-and-medison-enter-into-exclusive-distribution-agreement-to-commercialize-zejula-in-israel-idUSFWN1RO0PU", "country": "US", "domain_rank": 408, "title": "BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.034, "site_type": "news", "published": "2018-04-11T20:47:00.000+03:00", "replies_count": 0, "uuid": "5ecc00079c39931c09b1da2c87fff40836cc068d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tesaro-and-medison-enter-into-excl/brief-tesaro-and-medison-enter-into-exclusive-distribution-agreement-to-commercialize-zejula-in-israel-idUSFWN1RO0PU", "ord_in_thread": 0, "title": "BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel", "locations": [], "entities": {"persons": [], "locations": [{"name": "israel", "sentiment": "none"}, {"name": "israel", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "tesaro inc", "sentiment": "negative"}, {"name": "medison", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 11 (Reuters) - TESARO Inc:\n* TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULAÂ® IN ISRAEL\n* FURTHER TERMS OF AGREEMENT WERE NOT DISCLOSED * MEDISON WILL HAVE EXCLUSIVE RIGHT TO COMMERCIALIZE ZEJULA IN ALL INDICATIONS, EXCLUDING PROSTATE CANCER, IN ISRAEL\n* MEDISON TO ALSO BE RESPONSIBLE FOR ANY POTENTIAL PATIENT ACCESS PROGRAMS PRIOR TO REGULATORY APPROVAL Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-11T20:47:00.000+03:00", "crawled": "2018-04-12T14:09:07.013+03:00", "highlightTitle": ""}